Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825505 | 0.89 | TDP1 (0.72) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL6442808 | 0.88 | TDP1 (1.00) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| Fumaric Acid SCHEMBL4791789 | 0.87 | EGLN3 (0.64) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL5610837 | 0.87 | TDP1 (0.70) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL30058168 | 0.87 | TDP1 (0.70) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL5610799 | 0.86 | TDP1 (0.68) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL14740042 | 0.86 | TDP1 (0.68) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL5888624 | 0.86 | TDP1 (0.68) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL9814242 | 0.84 | TDP1 (0.84) | TDP1EGLN3LMNASMN1; SMN2HTT | |
| SCHEMBL3862944 | 0.84 | TDP1 (0.70) | TDP1EGLN3LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | claimed |
| CN-109354587-A | The preparation method and Pantoprazole Sodium of Pantoprazole Sodium | 成都天台山制药有限公司 | 2019-02-19 | — | — | CN | claimed |
| EP-2773378-B1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2016-08-10 | — | — | EP | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | claimed |
| JP-11148008-A | — | — | None | — | — | JP | disclosed |
| US-12612547-B2 | Semiconducting nanoparticle | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-04-28 | — | — | US | disclosed |
| EP-4232518-B1 | COMPOSITION | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-02-18 | — | — | EP | disclosed |
| US-12522714-B2 | Polysiloxane composition | MERCK PATENT GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4028485-B1 | NEW LIGANDS AND SEMICONDUCTING NANOPARTICLE | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4208904-B1 | DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-5026629-A | Thiosulfate fixing agent; imidazole compound; reduction of retained thiosulfate ion and dye stain | EASTMAN KODAK COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4782050-A | BACTERICIDES | PFIZER INC. (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0276942-A1 | 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0150380-A1 | Process for the preparation of N-vinylated unsaturated nitrogen-containing five-membered heterocycles | BAYER AG (DE) | 1985-08-07 | — | — | EP | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612547-B2 | Semiconducting nanoparticle | SCO2, NAF1, LBR | TDP1 4440/4885EGLN3 2959/4885LMNA 1022/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | TDP1 3148/4885EGLN3 414/4885LMNA 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.